Acer Medical Revolutionizes Ophthalmology with AI-Powered VeriSee Screening Solutions

Acer Medical has recently launched its AI-assisted screening software, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration. (Source: Fotor AI)

Transforming Eye Care with Advanced AI Technology

Acer Medical has unveiled its cutting-edge AI-assisted screening solutions, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration, at the Malaysian Ophthalmology Society Annual Congress. These innovative tools aim to enhance early detection and diagnosis of eye diseases, addressing the rising prevalence of diabetes and aging-related vision impairments in Malaysia.

Key Features of VeriSee AI Solutions

1. Real-Time Diagnosis with AI Precision: Powered by Intel® OpenVINO™ technology, VeriSee processes retinal images in seconds, delivering accurate detection of diabetic retinopathy and age-related macular degeneration. This rapid analysis enables healthcare professionals to provide timely treatment recommendations, improving patient outcomes.

   
   

2. Optimized Performance for Clinical Settings: Acer Medical’s collaboration with Intel ensures seamless integration of AI solutions in hospitals and clinics. OpenVINO™ accelerates AI inferencing with high throughput and low latency, making advanced diagnostics accessible across all levels of medical institutions.

   
   

3. Scalable Deployment Across Southeast Asia: VeriSee has already gained regulatory approval in Thailand, Indonesia, and the Philippines, demonstrating its adaptability to diverse healthcare systems. Acer Medical plans to expand its reach further, optimizing medical resource allocation and enhancing early disease detection capabilities.

   
   

Why This Matters: Rising Healthcare Challenges in Malaysia

1. Diabetes Epidemic: Malaysia has one of Southeast Asia’s highest diabetes prevalence rates, affecting 18.3% of adults aged 18 and above. Diabetic complications like retinopathy are on the rise, necessitating scalable solutions for early detection and management.

   
   

2. Aging Population: By 2040, 15.3% of Malaysia’s population will be aged 65 or older, increasing the incidence of age-related macular degeneration—a leading cause of vision impairment among seniors. AI-driven ophthalmic tools like VeriSee address this growing demand for preventive care.

   
   

Market Implications and Opportunities

The integration of AI in healthcare is revolutionizing diagnostics globally, with the market projected to grow at a CAGR of 38.5% from 2024 to 20302. Acer Medical’s VeriSee solutions align perfectly with this trend, offering significant market potential:

• Improved Efficiency for Healthcare Providers: By automating diagnostic processes, AI reduces the workload on ophthalmologists while ensuring consistent accuracy, enabling primary care facilities to deliver specialized services without additional staffing burdens.

  
  

• Enhanced Accessibility for Underserved Areas: Real-time image analysis allows clinics in rural or underserved regions to provide high-quality diagnostics without requiring specialized expertise on-site, bridging healthcare gaps in developing markets like Southeast Asia.

  
  

• Growth in AI-Driven Medical Imaging: The global AI medical imaging market is expected to grow at a CAGR of 34.8% from 2024 to 20303. Acer Medical’s focus on ophthalmology positions it as a leader in this rapidly expanding segment, offering scalable solutions for chronic disease management and preventive care.

🚀 Connect with Global Leaders in Ageing & Care Innovation!

Sourcingcares links international partners in aging care, long-term care, and health technology, fostering collaboration and driving solutions for a changing world. Our initiatives include Cares Expo Taipei—where the future of elder care takes shape!

🔗 Follow us for insights & opportunities:

📌 Facebook: sourcingcares

📌 LinkedIn: sourcingcares

📍 Explore more at Cares Expo Taipei!

Source: Digi Times Asia